Daily Edition · Page 1

THE DAILY INDEX

Technology, AI, software, security, crypto and business

Across today’s newsletters

Today’s Index

DEEPSEEK FAQ

DeepSeek's R1 model, which is similar to OpenAI's o1, caused a meltdown in the tech industry over the weekend. Many of the revelations that contributed to the meltdown were included in DeepSeek's announcement over Christmas and most of the breakthroughs in V3 were actually revealed with the release of the V2 model last January. DeepSeek-V2 introduced two important breakthroughs, DeepSeekMoE and DeepSeekMLA - the implications of these breakthroughs only became apparent with V3, which added a new approach to load balancing and multi-token prediction in training. The cost of training the model amounted to only $5.576 million, but that excludes the costs associated with prior research, experiments, and data. Many of the decisions DeepSeek made in training its model were due to the constraints of the chip ban - if DeepSeek had access to more powerful chips, it probably would have used a different method.

PUMP.FUN SET SINGLE-DAY REVENUE RECORD, RAKING IN $15.5 MILLION IN FEES FOLLOWING ANNIVERSARY

Pump.fun, a Solana-based memecoin launcher, achieved a record $15.5 million in single-day revenue on January 24 driven largely by the launch of Vine Coin, which reached a $425 million market cap amid speculation about the video platform's potential revival. The platform has processed $4 billion in the past two weeks and accumulated 2.5 million SOL in fees since launch. It faces new competition from Juptier's acquisition of rival platform Moonshot and potential legal challenges from investors who experienced losses on the platform.

HUGE STUDY FINDS CONSTELLATION OF HEALTH BENEFITS FOR OZEMPIC BEYOND WEIGHT LOSS

A new study that tracked millions of diabetes patient outcomes over a period of 3.5 years found that those on GLP-1 medications saw significant improvements across a staggering range of health concerns, far beyond anything clearly linked to weight or blood sugar. The patients experienced improvements in addiction and psychotic disorders and the risk of Alzheimer's was decreased. GLP-1RA drugs act on receptors that are expressed in brain areas involved in impulse control, reward, and addiction, which may potentially explain their effectiveness in curbing appetite and addiction disorders. While the findings are positive, the researchers found some issues that seemed to be exacerbated by taking GLP-1s, including an increase in risk for arthritis and pancreatitis.

WITH SUCCESSFUL NEW GLENN FLIGHT, BLUE ORIGIN MAY FINALLY BE TURNING THE CORNER

Blue Origin is finally a real rocket company with the successful launch of New Glenn. The company's next steps will be to get better at building engines and rockets and flying New Glenn regularly. Its current priorities are rate manufacturing and driving urgency around building the 'machine that builds the machine'. Blue Origin is the world's largest single-donor nonprofit, so it has zero incentive to operate like SpaceX.

MICROSOFT BUILDS OPEN SOURCE DOCUMENT DATABASE ON POSTGRESQL, SUGGESTS FERRETDB AS FRONT END

Developers looking to build something new on a document database now have more alternatives to choose from. Microsoft has launched a document database platform constructed on a relational PostgreSQL back end. It has suggested that users kick things off by implementing a FerretDB solution on the platform to get started. Microsoft has been increasingly accepting of the open source world. The joint development between Microsoft, PostgreSQL, and FerretDB is a threat to source-available MongoDB and Couchbase.

TLDR IndexPage 1